454709-94-5

Basic information

• Product Name: Carbamic acid, [(1R,2R)-2-aminocyclobutyl]-, 1,1-dimethylethyl ester, rel- (9CI)
• Synonyms: Carbamic acid, [(1R,2R)-2-aminocyclobutyl]-, 1,1-dimethylethyl ester, rel- (9CI);tert-butyl (1S,2S)-2-aminocyclobutylcarbamate
• CAS NO: 454709-94-5
• Molecular Formula: C9H18N2O2
• Molecular Weight: 186.25142
• Product Categories: N-BOC
• Mol File: 454709-94-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 285.8±29.0 °C(Predicted)
• Appearance: /
• Density: 1.06±0.1 g/cm3(Predicted)
• PKA: 12.23±0.40(Predicted)
• CAS DataBase Reference: Carbamic acid, [(1R,2R)-2-aminocyclobutyl]-, 1,1-dimethylethyl ester, rel- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1R,2R)-2-aminocyclobutyl]-, 1,1-dimethylethyl ester, rel- (9CI)(454709-94-5)
• EPA Substance Registry System: Carbamic acid, [(1R,2R)-2-aminocyclobutyl]-, 1,1-dimethylethyl ester, rel- (9CI)(454709-94-5)

Safety Data

• Hazardous Substances Data: 454709-94-5(Hazardous Substances Data)

Upstream product

• 1374222-84-0 benzyl tert-butyl (1S,2S)-cyclobutane-1,2-diylbiscarbamate 
• 1140194-63-3 (-)-(1R,2S)-2-(t-butyloxycarbonylamino)cyclobutane-carboxamide 
• 951173-22-1 (-)-(1S,2S)-2-[(tert-butyloxycarbonyl)amino]cyclobutanecarboxylic acid 
• 868364-63-0 (-)-(1R,2S)-2-[(tert-butyloxycarbonyl)amino]cyclobutanecarboxylic acid 
• 868364-62-9 methyl (-)-(1R,2S)-2-[(tert-butyloxycarbonyl)amino]cyclobutanecarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant articles and documents

Gadolinium complexes of highly rigid, open-chain ligands containing a cyclobutane ring in the backbone: Decreasing ligand denticity might enhance kinetic inertness

In an effort to explore novel ligand scaffolds for stable and inert lanthanide complexation in magnetic resonance imaging contrast agent research, three chiral ligands containing a highly rigid (1S,2S)-1,2-cyclobutanediamine spacer and different number of

Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions

The present invention relates to substituted xanthines of general formula wherein R1 to R4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).